Patents by Inventor Ursula Jeffry

Ursula Jeffry has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of treatment with CD80 extracellular domain polypeptides
    Patent number: 11789010
    Abstract: This application relates to use of CD80 (B7-1) extracellular domain (ECD) polypeptides and CD80-ECD fusion molecules and their use in methods of increasing the number of central memory T cells or for treatment for cancer or for use in cancer vaccine compositions.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: October 17, 2023
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Thomas Brennan, Barbara Sennino, Susannah D. Barbee, Ursula Jeffry
  • METHODS OF TREATMENT WITH CD80 EXTRACELLULAR DOMAIN POLYPEPTIDES
    Publication number: 20200182858
    Abstract: This application relates to use of CD80 (B7-1) extracellular domain (ECD) polypeptides and CD80-ECD fusion molecules and their use in methods of increasing the number of central memory T cells or for treatment for cancer or for use in cancer vaccine compositions.
    Type: Application
    Filed: April 27, 2018
    Publication date: June 11, 2020
    Inventors: Thomas BRENNAN, Barbara SENNINO, Susannah D. BARBEE, Ursula JEFFRY
  • Chimeric and humanized antibodies to ?5?1 integrin that modulate angiogenesis
    Patent number: 8309084
    Abstract: The present invention provides chimeric and humanized antibodies that specifically recognize ?5?1 integrin, and methods for using the antibodies for reducing or inhibiting angiogenesis in a tissue. Also provided are methods of determining therapeutically acceptable doses of the antibodies and pharmaceutical compositions including the same.
    Type: Grant
    Filed: January 19, 2011
    Date of Patent: November 13, 2012
    Assignee: Abbott Biotherapeutics Corp.
    Inventors: Vanitha Ramakrishnan, David Powers, Dale E. Johnson, Ursula Jeffry, Vinay Bhaskar
  • CHIMERIC AND HUMANIZED ANTIBODIES TO ALPHA5BETA1 INTEGRIN THAT MODULATE ANGIOGENESIS
    Publication number: 20110300133
    Abstract: The present invention provides chimeric and humanized antibodies that specifically recognize ?5?1 integrin, and methods for using the antibodies for reducing or inhibiting angiogenesis in a tissue. Also provided are methods of determining therapeutically acceptable doses of the antibodies and pharmaceutical compositions including the same.
    Type: Application
    Filed: January 19, 2011
    Publication date: December 8, 2011
    Applicant: Abbott Biotherapeutics Corp.
    Inventors: Vanitha RAMAKRISHNAN, David Powers, Dale E. Johnson, Ursula Jeffry, Vinay Bhaskar
  • Chimeric and humanized antibodies to ?5?1 integrin that modulate angiogenesis
    Patent number: 8017116
    Abstract: The present invention provides chimeric and humanized antibodies that specifically recognize ?5?1 integrin, and methods for using the antibodies for reducing or inhibiting angiogenesis in a tissue. Also provided are methods of determining therapeutically acceptable doses of the antibodies and pharmaceutical compositions including the same.
    Type: Grant
    Filed: August 17, 2007
    Date of Patent: September 13, 2011
    Assignee: Abbott Biotherapeutics Corp.
    Inventors: Vanitha Ramakrishnan, David Powers, Dale E. Johnson, Ursula Jeffry
  • Chimeric and humanized antibodies to ?5?1 integrin that modulate angiogenesis
    Patent number: 7897148
    Abstract: The present invention provides chimeric and humanized antibodies that specifically recognize ?5?1 integrin, and methods for using the antibodies for reducing or inhibiting angiogenesis in a tissue. Also provided are methods of determining therapeutically acceptable doses of the antibodies and pharmaceutical compositions including the same.
    Type: Grant
    Filed: September 7, 2007
    Date of Patent: March 1, 2011
    Assignee: Abbott Biotherapeutics Corp.
    Inventors: Vanitha Ramakrishnan, David Powers, Dale E. Johnson, Ursula Jeffry, Vinay Bhaskar
  • Chimeric and humanized antibodies to ?5?1 integrin that modulate angiogenesis
    Patent number: 7879987
    Abstract: The present invention provides chimeric and humanized antibodies that specifically recognize ?5?1 integrin, and methods for using the antibodies for reducing or inhibiting angiogenesis in a tissue. Also provided are methods of determining therapeutically acceptable doses of the antibodies and pharmaceutical compositions including the same.
    Type: Grant
    Filed: August 17, 2007
    Date of Patent: February 1, 2011
    Assignee: Facet Biotech Corporation
    Inventors: Vanitha Ramakrishnan, David Powers, Dale E. Johnson, Ursula Jeffry, Vinay Bhaskar
  • Chimeric and humanized antibodies to ?5?1 integrin that modulate angiogenesis
    Patent number: 7776585
    Abstract: The present invention provides chimeric and humanized antibodies that specifically recognize ?5?1 integrin, and methods for using the antibodies for reducing or inhibiting angiogenesis in a tissue. Also provided are methods of determining therapeutically acceptable doses of the antibodies and pharmaceutical compositions including the same.
    Type: Grant
    Filed: August 17, 2007
    Date of Patent: August 17, 2010
    Assignee: Facet Biotech Corporation
    Inventors: Vanitha Ramakrishnan, David Powers, Dale E. Johnson, Ursula Jeffry, Vinay Bhaskar
  • CHIMERIC AND HUMANIZED ANTIBODIES TO alpha5beta1 INTEGRIN THAT MODULATE ANGIOGENESIS
    Publication number: 20090259031
    Abstract: The present invention provides chimeric and humanized antibodies that specifically recognize ?5?1 integrin, and methods for using the antibodies for reducing or inhibiting angiogenesis in a tissue. Also provided are methods of determining therapeutically acceptable doses of the antibodies and pharmaceutical compositions including the same.
    Type: Application
    Filed: August 17, 2007
    Publication date: October 15, 2009
    Inventors: VANITHA RAMAKRISHNAN, David Powers, Dale E. Johnson, Ursula Jeffry, Vinay Bhaskar
  • USE OF ANTI-INTEGRIN ANTIBODIES FOR REDUCING SCAR TISSUE FORMATION
    Publication number: 20090041785
    Abstract: The present invention provides methods that enable the user to identify inhibitors of tissue granulation in and around a wound site, thereby limiting excessive scar formation as the wounded tissue heals. The some granulation inhibitors identified using the methods of the invention inhibit granulation in and around a wound site up to five fold, with a corresponding decrease in the formation of scar tissue when tested on retinal injuries. Granulation inhibitors that can be identified using the methods of the present invention include antibodies, peptides, nucleic acids (aptamers), and non-peptide small molecules.
    Type: Application
    Filed: September 19, 2008
    Publication date: February 12, 2009
    Inventors: Dale E. Johnson, Ursula Jeffry
  • CHIMERIC AND HUMANIZED ANTIBODIES TO ALPHA5BETA1 INTEGRIN THAT MODULATE ANGIOGENESIS
    Publication number: 20080260732
    Abstract: The present invention provides chimeric and humanized antibodies that specifically recognize ?5?1 integrin, and methods for using the antibodies for reducing or inhibiting angiogenesis in a tissue. Also provided are methods of determining therapeutically acceptable doses of the antibodies and pharmaceutical compositions including the same.
    Type: Application
    Filed: September 7, 2007
    Publication date: October 23, 2008
    Inventors: VANITHA RAMAKRISHNAN, David Powers, Dale E. Johnson, Ursula Jeffry, Vinay Bhaskar
  • CHIMERIC AND HUMANIZED ANTIBODIES TO alpha5beta1 INTEGRIN THAT MODULATE ANGIOGENESIS
    Publication number: 20080026033
    Abstract: The present invention provides chimeric and humanized antibodies that specifically recognize ?5?1 integrin, and methods for using the antibodies for reducing or inhibiting angiogenesis in a tissue. Also provided are methods of determining therapeutically acceptable doses of the antibodies and pharmaceutical compositions including the same.
    Type: Application
    Filed: August 17, 2007
    Publication date: January 31, 2008
    Inventors: Vanitha Ramakrishnan, David Powers, Dale Johnson, Ursula Jeffry
  • CHIMERIC AND HUMANIZED ANTIBODIES TO alpha5beta1 INTEGRIN THAT MODULATE ANGIOGENESIS
    Publication number: 20080026458
    Abstract: The present invention provides chimeric and humanized antibodies that specifically recognize ?5?1 integrin, and methods for using the antibodies for reducing or inhibiting angiogenesis in a tissue. Also provided are methods of determining therapeutically acceptable doses of the antibodies and pharmaceutical compositions including the same.
    Type: Application
    Filed: August 17, 2007
    Publication date: January 31, 2008
    Inventors: VANITHA RAMAKRISHNAN, David Powers, Dale Johnson, Ursula Jeffry, Vinay Bhaskar
  • Chimeric and humanized antibodies to ?5?1 integrin that modulate angiogenesis
    Patent number: 7285268
    Abstract: The present invention provides chimeric and humanized antibodies that specifically recognize ?5?1 integrin, and methods for using the antibodies for reducing or inhibiting angiogenesis in a tissue. Also provided are methods of determining therapeutically acceptable doses of the antibodies and pharmaceutical compositions including the same.
    Type: Grant
    Filed: April 23, 2004
    Date of Patent: October 23, 2007
    Assignee: PDL Biopharma, Inc.
    Inventors: Vanitha Ramakrishnan, David Powers, Dale E. Johnson, Ursula Jeffry
  • Chimeric and humanized antibodies to ?5?1 integrin that modulate angiogenesis
    Patent number: 7276589
    Abstract: The present invention provides chimeric and humanized antibodies that specifically recognize ?5?1 integrin, and methods for using the antibodies for reducing or inhibiting angiogenesis in a tissue. Also provided are methods of determining therapeutically acceptable doses of the antibodies and pharmaceutical compositions including the same.
    Type: Grant
    Filed: November 26, 2003
    Date of Patent: October 2, 2007
    Assignee: PDL Biopharma, Inc.
    Inventors: Vanitha Ramakrishnan, David Powers, Dale E. Johnson, Ursula Jeffry, Vinay Bhaskar
  • Chimeric and humanized antibodies to alpha5beta1 integrin that modulate angiogenesis
    Publication number: 20050163769
    Abstract: The present invention provides chimeric and humanized antibodies that specifically recognize ?5?1 integrin, and methods for using the antibodies for reducing or inhibiting angiogenesis in a tissue. Also provided are methods of determining therapeutically acceptable doses of the antibodies and pharmaceutical compositions including the same.
    Type: Application
    Filed: April 23, 2004
    Publication date: July 28, 2005
    Inventors: Vanitha Ramakrishnan, David Powers, Dale Johnson, Ursula Jeffry
  • Chimeric and humanized antibodies to alpha5beta1 integrin that modulate angiogenesis
    Publication number: 20050054834
    Abstract: The present invention provides chimeric and humanized antibodies that specifically recognize ?5?1 integrin, and methods for using the antibodies for reducing or inhibiting angiogenesis in a tissue. Also provided are methods of determining therapeutically acceptable doses of the antibodies and pharmaceutical compositions including the same.
    Type: Application
    Filed: November 26, 2003
    Publication date: March 10, 2005
    Inventors: Vanitha Ramakrishnan, David Powers, Dale Johnson, Ursula Jeffry, Vinay Bhaskar
  • Methods of production and use of anti-integrin antibodies for the control of tissue granulation
    Publication number: 20050002930
    Abstract: The present invention provides methods that enable the user to identify inhibitors of tissue granulation in and around a wound site, thereby limiting excessive scar formation as the wounded tissue heals. The some granulation inhibitors identified using the methods of the invention inhibit granulation in and around a wound site up to five fold, with a corresponding decrease in the formation of scar tissue when tested on retinal injuries. Granulation inhibitors that can be identified using the methods of the present invention include antibodies, peptides, nucleic acids (aptamers), and non-peptide small molecules.
    Type: Application
    Filed: April 2, 2004
    Publication date: January 6, 2005
    Inventors: Dale Johnson, Ursula Jeffry